1 option
CADTH reimbursement recommendation : for the treatment of neuromyelitis optica spectrum disorder : recommendation : reimburse with conditions Satralizumab (Enspryng) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Medicare--Finance.
- Medicare.
- Physical Description:
- 1 online resource (11 pages)
- Edition:
- Version: 1.0.
- Other Title:
- CADTH reimbursement recommendation
- Place of Publication:
- Ottawa, Ontario : Canadian Agency for Drugs and Technologies in Health, 2021.
- Summary:
- Clinical evidence suggests that Enspryng should be reimbursed for NMOSD in patients who are 12 years and older, anti-AQP4 positive, have had at least 1 NMOSD relapse in the 12 months before initiation despite an adequate trial of other accessible preventive treatments for NMOSD, or the patient cannot tolerate other preventive treatments for NMOSD. Patients must have an EDSS score of 6.5 points or less.
- Notes:
- Description based on online resource; title from PDF title page (Canadian Agency for Drugs and Technologies in Health, viewed April 20, 2023).
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.